Efficacy, Safety, and Tolerability of GRT6005 in Subjects With Moderate to Severe Chronic Low Back Pain.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Cebranopadol (Primary) ; Tapentadol
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Grunenthal
- 16 Jun 2017 A population PK analysis of cebranopadol using data from phase I and II trials, results published in the Clinical Pharmacokinetics
- 18 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.